FGEN

FibroGen Inc

FGEN, USA

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

https://www.fibrogen.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
FGEN
stock
FGEN

Is FibroGen (NASDAQ:FGEN) A Risky Investment? simplywall.st

Read more →
FGEN
stock
FGEN

FibroGen Receives FDA Orphan Drug Designation for Roxadustat in Myelodysplastic Syndromes, Phase 3 Protocol Set for Q4 2025 Submission Quiver Quantitative

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$43

Analyst Picks

Strong Buy

0

Buy

1

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-1.99

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-1,178.27 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very High

146.43 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-172.49 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 29.70% of the total shares of FibroGen Inc

1.

Armistice Capital, LLC

(8.3088%)

since

2025/06/30

2.

Vanguard Group Inc

(4.4027%)

since

2025/06/30

3.

Vanguard Total Stock Mkt Idx Inv

(2.8235%)

since

2025/07/31

4.

PRIMECAP Management Company

(2.2181%)

since

2025/06/30

5.

BlackRock Inc

(2.0958%)

since

2025/06/30

6.

Marshall Wace Asset Management Ltd

(1.7879%)

since

2025/06/30

7.

Vanguard Capital Opportunity Inv

(1.681%)

since

2025/06/30

8.

Geode Capital Management, LLC

(1.0889%)

since

2025/06/30

9.

HighTower Advisors, LLC

(0.9829%)

since

2025/06/30

10.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9383%)

since

2025/07/31

11.

Fidelity Extended Market Index

(0.5454%)

since

2025/07/31

12.

Two Sigma Investments LLC

(0.3489%)

since

2025/06/30

13.

State Street Corp

(0.3393%)

since

2025/06/30

14.

Renaissance Technologies Corp

(0.2765%)

since

2025/06/30

15.

UBS Group AG

(0.2544%)

since

2025/06/30

16.

Group One Trading, LP

(0.1783%)

since

2025/06/30

17.

Extended Equity Market Fund K

(0.1757%)

since

2025/06/30

18.

Fidelity Total Market Index

(0.1743%)

since

2025/07/31

19.

Fidelity Series Total Market Index

(0.1536%)

since

2025/07/31

20.

Acadian Global Small-Cap Equity CIT Cl A

(0.1254%)

since

2025/03/04

21.

Spartan Extended Market Index Pool F

(0.1051%)

since

2025/07/31

22.

Northern Trust Extended Eq Market Idx

(0.0921%)

since

2025/06/30

23.

NT Ext Equity Mkt Idx Fd - L

(0.0921%)

since

2025/06/30

24.

NT Ext Equity Mkt Idx Fd - NL

(0.0762%)

since

2025/06/30

25.

Spartan Total Market Index Pool G

(0.0608%)

since

2025/07/31

26.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0603%)

since

2024/12/31

27.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0592%)

since

2025/06/30

28.

Vanguard Balanced Index Inv

(0.0562%)

since

2025/07/31

29.

Morgan Stanley - Brokerage Accounts

(0.041%)

since

2025/06/30

30.

Goldman Sachs Group Inc

(0.0319%)

since

2025/03/31

31.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0219%)

since

2024/12/31

32.

Tower Research Capital LLC

(0.0196%)

since

2025/06/30

33.

Blackstone Alternative Multi-Strategy I

(0.0181%)

since

2024/12/31

34.

Advisor Group Holdings, Inc.

(0.0159%)

since

2025/06/30

35.

Gfg Capital, LLC

(0.0125%)

since

2025/06/30

36.

Bank of America Corp

(0.011%)

since

2025/06/30

37.

SSgA U.S. Total Market Index Strategy

(0.0109%)

since

2025/03/31

38.

Atlantic Trust Group, LLC

(0.0071%)

since

2025/06/30

39.

CIBC US Broad Market Index

(0.0047%)

since

2025/05/31

40.

SBI Securities Co Ltd

(0.0038%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-3.25

EPS Estimate

-0.095

EPS Difference

-3.155

Surprise Percent

-3321.0526%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(2)
Economic Moat
Wide Moat Company(8)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(6)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(3)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.